Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval. 2 "The burden of Crohn's disease on patients' ...

A new study showed that SOCS1 regulation of GM-CSF signaling is dose-dependent. The study, which involved generating a novel ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

ALBUQUERQUE, N.M. (KRQE) – An Albuquerque neurosurgeon lost his license after 26 patients brought claims against him, adding ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments. "We are very optimistic about the prospects of our ...

Q: I was just diagnosed with Type 2 diabetes. I feel like the doctor is expecting me to do his job! He loaded me down with a ...

As we increase the number of patients, we remain excited by the outlook for our Phase 1 clinical trial of soquelitinib for ...

Presented updated clinical and biomarker activity data at the IOVC in October 2024. Investigators reported ongoing improved ...

Preclinical Portfolio: includes development candidates WTX-712 and WTX-518, our IL-21 and binding protein resistant IL-18 INDUKINE molecules, respectively, for treatment of cancer, and WTX-921, an ...

This study aimed to investigate the association between the interleukin-1 beta (IL-1β) gene polymorphism (rs2853550) and the risk of rheumatoid arthritis (RA) in a sample of the Iraqi population. The ...

Analyst Judah Frommer of Morgan Stanley maintained a Buy rating on Mural Oncology Plc (MURA – Research Report), retaining the price target of ...